# A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

> **NCT06423352** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Mild to Moderate Hypertension

## Interventions

- **DRUG:** Zilebesiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06423352
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-05
- **Primary completion:** 2025-07-17
- **Final completion:** 2025-07-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06423352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06423352, "A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06423352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*